STOCK TITAN

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Tuesday, November 5, 2024. The company's management will host a webcast and conference call at 8:30 a.m. ET to discuss the financial results and recent highlights.

Investors can access the live webcast through the Investor Relations section of NeoGenomics' website at ir.neogenomics.com. The webcast will be archived for replay shortly after the call concludes. For those preferring to join via telephone, the dial-in numbers are (888) 506-0062 (domestic) or (973) 528-0011 (international), with the participant access code 676597. Callers are advised to dial in at least five minutes before the call starts.

NeoGenomics (NASDAQ: NEO), un'azienda leader nei servizi di test oncologici, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura dei mercati finanziari statunitensi il martedì 5 novembre 2024. La gestione dell'azienda ospiterà un webinar e una conference call alle 8:30 a.m. ET per discutere i risultati finanziari e i recenti sviluppi.

Gli investitori possono accedere al webinar dal vivo attraverso la sezione Relazioni con gli Investitori del sito web di NeoGenomics all'indirizzo ir.neogenomics.com. Il webinar sarà archiviato per la visione successiva poco dopo la conclusione della chiamata. Per coloro che preferiscono partecipare telefonicamente, i numeri da comporre sono (888) 506-0062 (nazionale) o (973) 528-0011 (internazionale), con il codice di accesso per i partecipanti 676597. Si consiglia ai chiamanti di comporre il numero almeno cinque minuti prima dell'inizio della chiamata.

NeoGenomics (NASDAQ: NEO), una empresa líder en servicios de pruebas oncológicas, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura de los mercados financieros de EE. UU. el martes 5 de noviembre de 2024. La dirección de la empresa llevará a cabo un webcast y una conferencia telefónica a las 8:30 a.m. ET para discutir los resultados financieros y los aspectos destacados recientes.

Los inversores pueden acceder al webcast en vivo a través de la sección de Relaciones con Inversores del sitio web de NeoGenomics en ir.neogenomics.com. El webcast será archivado para su reproducción poco después de que finalice la llamada. Para aquellos que prefieren unirse por teléfono, los números de marcado son (888) 506-0062 (nacional) o (973) 528-0011 (internacional), con el código de acceso para los participantes 676597. Se aconseja a los llamantes que marquen al menos cinco minutos antes de que comience la llamada.

NeoGenomics (NASDAQ: NEO)는 온콜로지 테스트 서비스의 선두 기업으로서, 2024년 3분기 재무 결과2024년 11월 5일 화요일 미국 금융시장 개장 전에 발표할 것이라고 발표했습니다. 회사의 경영진은 동부 표준시 기준 오전 8시 30분에 재무 결과 및 최근 주요 사항들을 논의하기 위해 웹캐스트와 컨퍼런스 콜을 진행할 것입니다.

투자자들은 NeoGenomics 웹사이트의 투자자 관계 섹션에서 ir.neogenomics.com을 통해 라이브 웹캐스트에 접속할 수 있습니다. 웹캐스트는 통화가 종료된 후 곧바로 다시 보기 위해 아카이브될 예정입니다. 전화로 참여하기를 원하는 분은 (888) 506-0062 (국내) 또는 (973) 528-0011 (국제)로 전화를 걸면 되며, 참여자 액세스 코드는 676597입니다. 통화가 시작되기 최소 5분 전에 전화해 주시기 바랍니다.

NeoGenomics (NASDAQ: NEO), une entreprise leader dans les services de tests oncologiques, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés financiers américains le mardi 5 novembre 2024. La direction de l'entreprise animera un webinaire et une conférence téléphonique à 8h30 ET pour discuter des résultats financiers et des points saillants récents.

Les investisseurs peuvent accéder au webinaire en direct via la section Relations avec les Investisseurs du site Web de NeoGenomics à l'adresse ir.neogenomics.com. Le webinaire sera archivé pour une rediffusion peu de temps après la fin de l'appel. Pour ceux qui préfèrent participer par téléphone, les numéros à composer sont (888) 506-0062 (national) ou (973) 528-0011 (international), avec le code d'accès des participants 676597. Il est conseillé aux appelants de composer le numéro au moins cinq minutes avant le début de l'appel.

NeoGenomics (NASDAQ: NEO), ein führendes Unternehmen im Bereich der Onkologie-Testdienstleistungen, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor der Eröffnung der US-Finanzmärkte am Dienstag, den 5. November 2024, veröffentlichen wird. Das Management des Unternehmens wird um 8:30 Uhr ET einen Webcast und eine Telefonkonferenz abhalten, um die Finanzergebnisse und aktuelle Highlights zu besprechen.

Investoren können über den Bereich Investor Relations auf der Website von NeoGenomics auf den Live-Webcast zugreifen unter ir.neogenomics.com. Der Webcast wird kurz nach dem Ende des Calls für eine Wiederholung archiviert. Für diejenigen, die lieber telefonisch teilnehmen möchten, sind die Einwahlnummern (888) 506-0062 (national) oder (973) 528-0011 (international), mit dem Teilnehmerzugangscode 676597. Anrufer wird geraten, mindestens fünf Minuten vor Beginn des Calls einzuwählen.

Positive
  • None.
Negative
  • None.

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.

The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.

To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 676597.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

FAQ

When will NeoGenomics (NEO) report its Q3 2024 financial results?

NeoGenomics (NEO) will report its third quarter 2024 financial results on Tuesday, November 5, 2024, before the U.S. financial markets open.

How can investors access NeoGenomics' (NEO) Q3 2024 earnings call?

Investors can access NeoGenomics' Q3 2024 earnings call via a webcast on the company's website (ir.neogenomics.com) or by phone at (888) 506-0062 (domestic) or (973) 528-0011 (international) using the access code 676597.

What time is NeoGenomics' (NEO) Q3 2024 earnings call scheduled for?

NeoGenomics' (NEO) Q3 2024 earnings call is scheduled for 8:30 a.m. ET on Tuesday, November 5, 2024.

Will NeoGenomics (NEO) provide a replay of its Q3 2024 earnings call?

Yes, NeoGenomics (NEO) will archive the webcast of its Q3 2024 earnings call, making it available for replay shortly after the call concludes.

NeoGenomics, Inc.

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Stock Data

2.05B
126.69M
1.28%
99.7%
3.31%
Diagnostics & Research
Services-testing Laboratories
Link
United States of America
FORT MYERS